This was the stock's third consecutive day of gains.
NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
NEW YORK, NY / ACCESSWIRE / December 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
NEW YORK, NY / ACCESSWIRE / December 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") ...
The announcement comes directly from Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated, with the signatory on the report being Jonathan Biller, the Executive Vice President and Chief Legal Officer ...
Dec 20 (Reuters) - The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' (VRTX.O), opens new tab next-generation treatment for a rare and progressive genetic disease ...
CNBC’s Jim Cramer delivers his daily Mad Dash. Luigi Mangione, CEO killing suspect, pleads not guilty to state terror and murder charges in Manhattan court Congress ...
Vertex Pharmaceuticals (NASDAQ:VRTX ... However, Vertex faces competition from other biotech firms like Gilead Sciences and Biogen, which also focus on innovative treatments. On December 19, 2024, ...
On Thursday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced results from its Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR), a disorder that causes pain in the ...
In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the other stocks Jim Cramer talked about this week. Jim Cramer, host of Mad ...